Terms: = Breast cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
142 results:
1. siRNA treatment targeting integrin α11 overexpressed via ezh2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract] [Full Text] [Related]
2. Hypoxia-activated XBP1s recruits HDAC2-ezh2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α.
Chen H; Yu S; Ma R; Deng L; Yi Y; Niu M; Xu C; Xiao ZJ
Cell Death Differ; 2024 Apr; 31(4):447-459. PubMed ID: 38413797
[TBL] [Abstract] [Full Text] [Related]
3. A Metabolic-Epigenetic Mechanism Directs Cell Fate and Therapeutic Sensitivity in breast cancer.
Bernard MJ; Goldstein AS
Cancer Res; 2024 May; 84(9):1382-1383. PubMed ID: 38330100
[TBL] [Abstract] [Full Text] [Related]
4. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
5. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
[TBL] [Abstract] [Full Text] [Related]
6. Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets.
Chen X; Li H
PLoS One; 2024; 19(1):e0297203. PubMed ID: 38215156
[TBL] [Abstract] [Full Text] [Related]
7. Design, synthesis, and evaluation of VHL-based ezh2 degraders for breast cancer.
Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
[TBL] [Abstract] [Full Text] [Related]
8. Dual target PARP1/ezh2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
[TBL] [Abstract] [Full Text] [Related]
9. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (ezh2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
10. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract] [Full Text] [Related]
11. Phosphorylation of ezh2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
Yu F; Li L; Zhang M; Sun S
BMC Cancer; 2023 Oct; 23(1):948. PubMed ID: 37803297
[TBL] [Abstract] [Full Text] [Related]
12. Validation of ezh2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of a Potent Dual ezh2-BRD4 Inhibitor for the treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the ezh2-E-cadherin/RHOB pathway.
Lei C; Li S; Fan Y; Hua L; Pan Q; Li Y; Long Z; Yang R
Cancer Biol Ther; 2022 Dec; 23(1):1-13. PubMed ID: 36329030
[TBL] [Abstract] [Full Text] [Related]
15. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal breast cancer.
Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
[TBL] [Abstract] [Full Text] [Related]
16. Combined inhibition of ezh2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses.
Adibfar S; Masjedi A; Nazer A; Rashidi B; Karpisheh V; Izadi S; Hassannia H; Gholizadeh Navashenaq J; Mohammadi H; Hojjat-Farsangi M; Tarokhian H; Jadidi-Niaragh F
Life Sci; 2022 Nov; 309():121008. PubMed ID: 36179812
[TBL] [Abstract] [Full Text] [Related]
17. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer.
Kitajima S; Tani T; Springer BF; Campisi M; Osaki T; Haratani K; Chen M; Knelson EH; Mahadevan NR; Ritter J; Yoshida R; Köhler J; Ogino A; Nozawa RS; Sundararaman SK; Thai TC; Homme M; Piel B; Kivlehan S; Obua BN; Purcell C; Yajima M; Barbie TU; Lizotte PH; Jänne PA; Paweletz CP; Gokhale PC; Barbie DA
Cancer Cell; 2022 Oct; 40(10):1128-1144.e8. PubMed ID: 36150391
[TBL] [Abstract] [Full Text] [Related]
18. TGF-β1/Smad3 upregulates UCA1 to promote liver fibrosis through DKK1 and miR18a.
Yang Z; Zhang H; Yin M; Cheng Z; Jiang P; Feng M; Liu Z; Liao B
J Mol Med (Berl); 2022 Oct; 100(10):1465-1478. PubMed ID: 36001113
[TBL] [Abstract] [Full Text] [Related]
19. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through ezh2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract] [Full Text] [Related]
20. IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.
Ong LT; Lee WC; Ma S; Oguz G; Niu Z; Bao Y; Yusuf M; Lee PL; Goh JY; Wang P; Yong KSM; Chen Q; Wang W; Ramasamy A; Hoon DSB; Ditzel HJ; Tan EY; Lee SC; Yu Q
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2201376119. PubMed ID: 35878022
[TBL] [Abstract] [Full Text] [Related]
[Next]
